FAU Erlangen-Nuernberg
Erlangen, Bavaria, 91054, Germany
Location status: Recruiting
NCT Number: NCT06611254
In this clinical study vascular dynamics in the neonatal brain and kidney will be monitored by CUES and ULM before, during and after hypothermia treatment in neonates with asphyxia.
Interested in participating?
Request InfoAll sexes
Observational
Erlangen, Bavaria, 91054, Germany
Location status: Recruiting
Perinatal asphyxia (PA) is the reduced supply of oxygen to vital organs during or immediately after birth. PA is one of the most common causes of neonatal mortality in full-term infants worldwide and of hypoxic-ischemic encephalopathy (HIE) with subsequent neurological deficits (spastic cerebral palsy). In addition to brain damage, perinatal asphyxia often leads to dysfunction of other organs. It is not uncommon for this to be accompanied by transient renal failure.
Hypothermia treatment is an established therapeutic measure for neuroprotection in clinical indications of HIE. This involves lowering the core body temperature of affected children to 33.5°C for 72 hours. The therapeutic effect is thought to be due to multifactorial mechanisms, including a reduction in endothelial dysfunction, reduced excretion of free radicals and attenuation of the inflammatory cascade.
In the guidelines for hypothermia treatment in neonatal asphyxia, regular ultrasound examinations are prescribed to clarify damage to the central nervous system (CNS) before, during and after hypothermia treatment.1 In infants, transfontal ultrasound makes it possible to visualize brain structures, vessels and their flow velocities.
The intravenous use of ultrasound contrast enhancers as an aid also opens up the possibility of recording the tissue perfusion of the CNS and kidneys, including the smallest vessels.8 This could provide significantly more information compared to conventional methods and expand our knowledge of the pathophysiology and individual status of tissue perfusion in patients.
For example, two studies at Erlangen University Hospital have successfully used contrast-enhanced ultrasound (CEUS) with the contrast agent known as SonoVue® to visualize postoperative perfusion of the brain after pediatric cardiac surgery.
In this clinical study, the new CEUS measurement and imaging technique will be used before, during and after hypothermia treatment in neonates with asphyxia. A contrast agent (SonoVue®) will be administered during the routine ultrasound examination and improved tissue visualization will be achieved. The aim is to gain new insights into brain and kidney perfusion as part of the treatment and to better assess the extent of organ damage in the individual patient through more specific vascular imaging. Improved visualization and assessment of the end-stream area will provide information on processes that promote the development of HIE and renal failure. Finally, the aim is to compare diagnostic and prognostic methods with the currently recommended measures. The CEUS is to be examined as a possible diagnostic imaging tool and possibly a supplement to existing diagnostic methods.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
-->Offer of a further informative discussion/repeated explanation with the parents/legal representatives before the second measurement in order to answer any questions that may have arisen
Exclusion criteria
CEUS is a contrast based ultrasound technique and ULM (Ultrasound Localization Microscopy) is a post-processing bioinformatical method to quantify microvascular architecture and perfusion dynamics.
Time frame: before(T1, within the first 6hours of life), during hypothermia treatment(T2, 6-78hours of life), after treatment (T3, within first week of life)
All CEUS outcomes will be generated in order to achieve time intensity curves in contrast enhanced ultrasound analysis
Time frame: before(T1, within the first 6hours of life), during hypothermia treatment(T2, 6-78hours of life), after treatment (T3, within first week of life)
PE (Peak-Enhancement)
Time frame: before(T1, within the first 6hours of life), during hypothermia treatment(T2, 6-78hours of life), after treatment (T3, within first week of life)
WiAUC (Wash-in Area Under the Curve (AUC(TI: TTP)))
Time frame: before(T1, within the first 6hours of life), during hypothermia treatment(T2, 6-78hours of life), after treatment (T3, within first week of life)
WiAUC (Wash-in Area Under the Curve (AUC(TI: TTP)))
Time frame: before(T1, within the first 6hours of life), during hypothermia treatment(T2, 6-78hours of life), after treatment (T3, within first week of life)
RT (Rise Time)
Time frame: before(T1, within the first 6hours of life), during hypothermia treatment(T2, 6-78hours of life), after treatment (T3, within first week of life)
mTT (mean Transit Time local) (mTT-TI))
Time frame: before(T1, within the first 6hours of life), during hypothermia treatment(T2, 6-78hours of life), after treatment (T3, within first week of life)
TTP (Time to Peak)
Time frame: before(T1, within the first 6hours of life), during hypothermia treatment(T2, 6-78hours of life), after treatment (T3, within first week of life)
WiR (Wash-in-Rate )
Time frame: before(T1, within the first 6hours of life), during hypothermia treatment(T2, 6-78hours of life), after treatment (T3, within first week of life)
WiPI (Wash-in Perfusion Index (WiAUC/RT))
Time frame: before(T1, within the first 6hours of life), during hypothermia treatment(T2, 6-78hours of life), after treatment (T3, within first week of life)
WoAUC (Wash-out AUC (AUC(TTP:TO)))
Time frame: before(T1, within the first 6hours of life), during hypothermia treatment(T2, 6-78hours of life), after treatment (T3, within first week of life)
WiWoAUC (Wash-in- und Wash-out-AUC (WiAUC+WoAUC))
Time frame: before(T1, within the first 6hours of life), during hypothermia treatment(T2, 6-78hours of life), after treatment (T3, within first week of life)
FT (Fall Time - (TO-TTP))
Time frame: before(T1, within the first 6hours of life), during hypothermia treatment(T2, 6-78hours of life), after treatment (T3, within first week of life)
WOR (Wash-out-Rate) QOF (Quality Of Fit between the echo-power signal and f(t)
Time frame: before(T1, within the first 6hours of life), during hypothermia treatment(T2, 6-78hours of life), after treatment (T3, within first week of life)
QOF (Quality Of Fit between the echo-power signal and f(t)
Time frame: before(T1, within the first 6hours of life), during hypothermia treatment(T2, 6-78hours of life), after treatment (T3, within first week of life)
Near-infrared spectroscopy Non-invasive measurement of oxygen saturation in tissue using a probe that is attached to the head.62 This procedure is already firmly established in the field of pediatric surgery and pediatric cardiology interventions at the University Hospital Erlangen. The probe is attached before the start of the first measurement time point and removed after the end of the third measurement time point. There is no risk of side effects.
Time frame: before(T1, within the first 6hours of life), during hypothermia treatment(T2, 6-78hours of life), after treatment (T3, within first week of life)
CEUS imaging for cerebral perfusion in asphyxia
Time frame: before(T1, within the first 6hours of life), during hypothermia treatment(T2, 6-78hours of life), after treatment (T3, within first week of life)
CEUS imaging for renal perfusion in asphyxia
Time frame: T1,T2,T3
Correlation coefficient (R) between CEUS curve and NIRS
Time frame: Month of life: 3-4 and 6-24
Neurological status of the patients will be assessed by the score "Bayley Scales of Infant and Toddler Development"
Time frame: once within first two years of life
MRI Weeke Score
Time frame: T1,T2, T3
CEUS curve at T1,T2, T3
Time frame: T1, T2, T3
Lactate (mmol/l)
Time frame: T1 -T3 and through study completion
Number (n) of ETPs in EEG
Time frame: T1 -T3 and through study completion
frequency EEG (Hz)
Time frame: T1 -T3 and through study completion, an average of 3 years
GFR (ml/min/1,73 m2)
Time frame: T1 -T3 and through study completion, an average of 3 years
urea (mg/dl)
Time frame: T1 -T3 and through study completion
standardized urinary status
Time frame: T1, T2, T3
kreatininekinase (U/l)
Time frame: T1, T2, T3
LDH (U/l)
Interested in participating?
Request InfoUniversity of Erlangen-Nürnberg Medical School
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06322732
Brain Diseases, Brain Ischemia
Paris, Île-de-France Region, France
View Trial DetailsNCT06747260
Brain Diseases, Brain Injuries
Budapest, Hungary
View Trial DetailsNCT06746532
Brain Diseases, Brain Ischemia
Budapest, Hungary
View Trial DetailsNCT07831746
Brain Diseases, Brain Ischemia
View Trial Details